SPTBN2 and digestive system neoplasm: For DSS, high expression of SPTBN2 was also associated with poorer survival in most cancers, including KIRC, PAAD, stomach and esophageal carcinoma (STES), and stomach adenocarcinoma (STAD) (Fig. 2b, p < 0.05).